Home › NDC Lookup › RxCUI directory › RxCUI 672149

Lapatinib 250 MG Oral Tablet — RxCUI 672149

RxNorm drug concept · Semantic clinical drug
RxCUI 672149 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI672149
Official nameLapatinib 250 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aslapatinib 250 MG (as lapatinib ditosylate 398 MG) Oral Tablet
FDA products mapped4
Package NDCs mapped4
Reported Medicaid activity (SDUD)127 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lapatinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats certain HER2-positive breast cancers. It is used with capecitabine for advanced or metastatic disease after other treatments, or with letrozole in postmenopausal women wh...
  • Take it by mouth once a day, all the tablets together, at least an hour before or an hour after a meal. Food changes how much drug your body absorbs, so keep the timing consistent....
  • Diarrhea is the most common, along with nausea, vomiting, rash, hand-foot skin reaction, and fatigue. Diarrhea often starts early, so tell your care team at the first loose stool;...
  • Call right away for yellow skin or eyes, dark urine, severe or lasting diarrhea, new cough or trouble breathing, fainting or a racing heartbeat, swelling or breathlessness, or a bl...
📖 Read our full Lapatinib guide →

🕸️ Concept Web — How Lapatinib 250 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lapatinib 250 MG Oral Tablet RxCUI 672149

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Lapatinib 480167
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tykerb 659616
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lapatinib Oral Tablet 672148
    • Lapatinib Oral Product 1162549
    • Lapatinib Pill 1162550
    • Lapatinib Oral Tablet [Tykerb] 672151
    • Tykerb Oral Product 1186914
    • Tykerb Pill 1186915
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lapatinib 250 MG SCDC · 672147
  • Lapatinib Oral Tablet SCDF · 672148
  • Lapatinib Oral Product SCDG · 1162549
  • Lapatinib Pill SCDG · 1162550

Brand-Name Concepts

  • Lapatinib 250 MG Oral Tablet [Tykerb] SBD · 672152
  • Lapatinib 250 MG [Tykerb] SBDC · 672150
  • Lapatinib Oral Tablet [Tykerb] SBDF · 672151
  • Tykerb Oral Product SBDG · 1186914
  • Tykerb Pill SBDG · 1186915
  • Tykerb BN · 659616

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 672149 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00078-0671-19 150 TABLET in 1 BOTTLE (0078-0671-19) TYKERB Novartis Pharmaceuticals Corporation 2016-08-03
00480-3237-51 150 TABLET, FILM COATED in 1 BOTTLE (0480-3237-51) Lapatinib Teva Pharmaceuticals, Inc. 2024-12-19
42291-0035-15 150 TABLET, FILM COATED in 1 BOTTLE (42291-035-15) Lapatinib AvKARE 2025-03-12
68180-0801-36 150 TABLET in 1 BOTTLE (68180-801-36) Lapatinib Lupin Pharmaceuticals, Inc. 2020-09-29
Observed labelers: AvKARE (1) · Lupin Pharmaceuticals, Inc. (1) · Novartis Pharmaceuticals Corporation (1) · Teva Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.